Salix Pharmaceuticals Ltd. (SLXP)

SLXP (NASDAQ:Drugs)
$66.42
neg -0.41
-0.61%
Today's Range: 66.33 - 67.38 | SLXP Avg Daily Volume: 559,700
Last Update: 06/19/13 - 4:00 PM EDT
Volume: 423,941
YTD Performance: 65.13%
Open: $67.26
Previous Close: $66.83
52 Week Range: $37.52 - $68.62
Oustanding Shares: 61,304,811
Market Cap: 4,097,000,519
6-Month Chart
TheStreet Ratings Grade for SLXP
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 9 8
Moderate Buy 1 1 1 1
Hold 6 7 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.87 2.00 1.73 1.87
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 07/13/04
Price Earnings Ratio: 55.23
Price Earnings Comparisons:
SLXP Sector Avg. S&P 500
55.23 55.20 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
35.28% 24.13% 81.41%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.10 2.16 0.46
Net Income -26.50 -2.47 0.00
EPS -29.90 -2.24 0.00
Earnings for SLXP:
EBITDA 0.27B
Revenue 0.74B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $0.82 $0.97 $3.59 $4.57
Number of Analysts 1 1 1 1
High Estimate $0.82 $0.97 $3.59 $4.57
Low Estimate $0.82 $0.97 $3.59 $4.57
Prior Year $0.79 $0.95 $3.00 $3.59
Growth Rate (Year over Year) 3.80% 2.11% 19.67% 27.30%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishSalix Pharmaceuticals downgraded at ThinkEquity

Jul 30, 2012 | 8:19 AM EDT

SLXP was downgraded from Buy to Hold, ThinkEquity said. $53 price target. Company lacks potential catalysts for the next year. 

bearishSalix Pharmaceuticals downgraded at Cantor

Jul 30, 2012 | 7:11 AM EDT

SLXP was downgraded to Hold, Cantor Fitzgerald said. $59 price target. Company is facing another pipeline setback with Relistor. 

Strength in Adversity

By

Ed Ponsi

 | May 17, 2012 | 11:00 AM EDT

If you're a buyer, look at these names as opposed to some of the go-to stocks of the past year.

bullishSalix Pharmaceuticals numbers raised at Jefferies

May 8, 2012 | 8:07 AM EDT

Shares of SLXP now seen reaching $63, Jefferies said. Estimates also raised on beat and raise. Buy rating.

bearishSalix downgraded at Auriga

Apr 10, 2012 | 7:39 AM EDT

SLXP was downgraded to Hold, Auriga USA said. $51 price target. Stock is already pricing in potential approval of Relistor and Crofelemer.

Beating Inflation With Biotech

By

John Reese

 | Mar 13, 2012 | 7:30 AM EDT

Biotech and pharma companies have the biggest edge in pricing power.

bullishSalix Pharmaceuticals upgraded at Auriga

Feb 28, 2012 | 8:06 AM EST

SLXP was upgraded to Buy from Hold, Auriga said.  $54 price target.  2012 guidance appears conservative. 

bearishSalix Pharmaceuticals numbers cut at Credit Suisse

Feb 28, 2012 | 7:59 AM EST

Shares of SLXP now seen reaching $53, according to Credit Suisse. Estimates also reduced, Company is seeing higher operating costs. Outperform rating.

The Week Ahead: Investors Eye GDP, Manufacturing Data; E...

By

Ken Shreve

 | Feb 26, 2012 | 4:00 PM EST

Contributor Ken Shreve takes a look at upcoming economic data and some key earnings reports for the week of Feb. 27

bearishSalix Pharmaceuticals downgraded at JMP

Jan 23, 2012 | 7:37 AM EST

SLXP was downgraded from Outperform to Market Perform, JMP Securities said. Valuation call, as the stock is already pricing in a lot of good news.

Columnist Conversation / Market Updates

Brutal, But Here is Something Fun
By

Brian Sozzi

 | Jun 20, 2013 | 4:57 AM EDT
Brutal day for the markets, one that really seemed more than a typical post-Fed announcement knee-jerk reaction. So, wh...

Bullish Case for the Bonds (TLT)
By

Toni Hansen

 | Jun 20, 2013 | 1:22 AM EDT
Has the TLT finally found support? More importantly, can it hold it? I think there is a case to be made for it... Here i...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.